Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$3.00 CAD
Change Today +0.40 / 15.38%
Volume 20.8K
As of 3:52 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

fennec pharmaceuticals inc (FRX) Snapshot

Open
C$2.73
Previous Close
C$2.60
Day High
C$3.18
Day Low
C$2.73
52 Week High
05/27/14 - C$7.77
52 Week Low
12/23/14 - C$2.01
Market Cap
31.9M
Average Volume 10 Days
4.8K
EPS TTM
C$-0.08
Shares Outstanding
10.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FENNEC PHARMACEUTICALS INC (FRX)

Related News

No related news articles were found.

fennec pharmaceuticals inc (FRX) Related Businessweek News

No Related Businessweek News Found

fennec pharmaceuticals inc (FRX) Details

Fennec Pharmaceuticals Inc., together with its subsidiaries, operates as a biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. Its lead product candidates include Sodium Thiosulfate, a water soluble thiol compound, which is in phase III clinical trials that act as a chemical reducing agent for the prevention of cisplatin induced hearing loss or ototoxicity in children; and Eniluracil, an oral irreversible dihydropyrimidine dehydrogenase inhibitor for the rapid break down of 5-FU in the body, which has completed phase II clinical trials for the treatment of metastatic breast cancer. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

1 Employees
Last Reported Date: 03/31/15
Founded in 1996

fennec pharmaceuticals inc (FRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $218.5K
Interim Chief Financial Officer
Total Annual Compensation: $144.7K
Compensation as of Fiscal Year 2014.

fennec pharmaceuticals inc (FRX) Key Developments

Fennec Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Fennec Pharmaceuticals Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's net income was $177,000 compared to net loss of $3,194,000 a year ago. Net cash used in operating activities was $418, as compared to $378 during the same period in 2014. This increase is due to increased cash outlays for research and development expenses incurred for ongoing STS Phase III trials, STS product development and general and administrative costs associated with the Company's strategic initiatives designed to further develop new markets and partnering opportunities.

Fennec Pharmaceuticals, Inc. Announces Availability of Siopel 6 Study Abstract for Asco 2015 Meeting

Fennec Pharmaceuticals Inc. announced that sodium thiosulfate (STS) will be featured in the abstract titled "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." at the American Society of Clinical Oncology (ASCO) being held May 29 through June 2, 2014 in Chicago, IL. The abstract provides the interim safety results from 94 patients in the study. These results show no adverse outcome related to STS on the anti tumor efficacy in patients receiving cisplatin monotherapy for standard risk hepatoblastoma. Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies. Unfortunately platinum-based therapies cause ototoxicity in many patients, and are particularly harmful to the survivors of pediatric cancer. In the U.S., it is estimated that over 2,000 children are diagnosed with local cancers that may receive platinum based chemotherapy and globally over 5,000. The incidence of hearing loss in these children depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement. STS has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies are closed to recruitment. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Fennec Pharmaceuticals Inc. Reports Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Fennec Pharmaceuticals Inc. reported consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $790,000 compared to $416,000 reported a year ago. Net income was $1,388,000 or $0.14 per basic share compared to $1,112,000 or $0.12 per basic share reported a year ago. The increase in the net loss from operations excluding the non-cash impact of derivatives is primarily due to an increase in general and administrative non-cash expenses associated with equity based compensation. For the year, the company reported loss from operations of $2,877,000 compared to $1,931,000 reported a year ago. Net loss was $2,176,000 or $0.22 per basic share compared to net income of $1,845,000 or $0.19 per basic share reported a year ago. The increase in the net loss from operations excluding the non-cash impact of derivatives is primarily due to the non-cash expense of issuing equity based compensation and select corporate administrative expenses tied to the 2014 warrant exchange, reverse stock split and corporate name change.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRX:CN C$3.00 CAD +0.40

FRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FRX.
View Industry Companies
 

Industry Analysis

FRX

Industry Average

Valuation FRX Industry Range
Price/Earnings 14.4x
Price/Sales -- Not Meaningful
Price/Book 26.2x
Price/Cash Flow 22.3x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FENNEC PHARMACEUTICALS INC, please visit www.fennecpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.